MedTrace Logo

Allograft Dysfunction in Heart Transplant

NCT03102125 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2026-05-01

No results posted yet for this study

Summary

The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.

Conditions

  • Heart Transplant Failure and Rejection

Interventions

DRUG

Regadenoson

For use in stress myocardial perfusion imaging.

Sponsors & Collaborators

  • Paul Kim

    lead OTHER

Principal Investigators

  • Paul Kim, MD · UC San Diego

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2027-01-01
Completion
2027-01-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03102125 on ClinicalTrials.gov